US2664423A
(en)
|
1952-03-12 |
1953-12-29 |
Searle & Co |
4-(cyclopentanopolyhydrophenanthr-17-yl) imidazoles and derivatives thereof
|
GB972672A
(en)
|
1960-01-14 |
1964-10-14 |
Ciba Ltd |
Pharmaceutical preparations containing compounds of the androstane series
|
US3060174A
(en)
|
1960-01-14 |
1962-10-23 |
Ciba Geigy Corp |
Esters of the androstane series and process for their manufacture
|
US3313809A
(en)
|
1965-03-05 |
1967-04-11 |
Sterling Drug Inc |
Steroido[21, 20-d]isoxazoles
|
US3317520A
(en)
|
1965-03-05 |
1967-05-02 |
Sterling Drug Inc |
Steroido[20, 21-c]pyrazoles and intermediates
|
DE1493169A1
(en)
|
1965-09-03 |
1969-06-04 |
Schering Ag |
Process for the preparation of 5 beta-bisnorcholane derivatives
|
US3480621A
(en)
|
1967-01-17 |
1969-11-25 |
Phytogen Prod Inc |
Steroid ketal
|
CH621803A5
(en)
|
1974-08-08 |
1981-02-27 |
Siphar Sa |
|
JPS563000Y2
(en)
|
1976-07-27 |
1981-01-23 |
|
|
JPS563000A
(en)
|
1979-06-20 |
1981-01-13 |
Green Cross Corp:The |
Water-soluble cholesterol derivative
|
US4316885A
(en)
|
1980-08-25 |
1982-02-23 |
Ayerst, Mckenna And Harrison, Inc. |
Acyl derivatives of rapamycin
|
US4469689A
(en)
|
1983-03-30 |
1984-09-04 |
The Upjohn Company |
Sulfonate containing ester prodrugs of corticosteroids
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
US4650803A
(en)
|
1985-12-06 |
1987-03-17 |
University Of Kansas |
Prodrugs of rapamycin
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
US4877611A
(en)
|
1986-04-15 |
1989-10-31 |
Ribi Immunochem Research Inc. |
Vaccine containing tumor antigens and adjuvants
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
US5843708A
(en)
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
IT1216687B
(en)
|
1988-04-01 |
1990-03-08 |
Boehringer Biochemia Srl |
PLATINUM (II) COMPLEXES, THEIR PREPARATION AND USE AS ANTI-CANCER PRODUCTS.
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
ATE139258T1
(en)
|
1990-01-12 |
1996-06-15 |
Cell Genesys Inc |
GENERATION OF XENOGENE ANTIBODIES
|
US5028726A
(en)
|
1990-02-07 |
1991-07-02 |
The University Of Vermont And State Agricultural College |
Platinum amine sulfoxide complexes
|
US5264428A
(en)
|
1990-02-16 |
1993-11-23 |
Kanoldt Arzneimittel Gmbh |
Use of stigmasta-4-en-3-one in the treatment of androgen dependent diseases
|
US5637459A
(en)
|
1990-06-11 |
1997-06-10 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: chimeric selex
|
WO1991019813A1
(en)
|
1990-06-11 |
1991-12-26 |
The University Of Colorado Foundation, Inc. |
Nucleic acid ligands
|
US5707796A
(en)
|
1990-06-11 |
1998-01-13 |
Nexstar Pharmaceuticals, Inc. |
Method for selecting nucleic acids on the basis of structure
|
US5496938A
(en)
|
1990-06-11 |
1996-03-05 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligands to HIV-RT and HIV-1 rev
|
US5660985A
(en)
|
1990-06-11 |
1997-08-26 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands containing modified nucleotides
|
US6011020A
(en)
|
1990-06-11 |
2000-01-04 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
US5683867A
(en)
|
1990-06-11 |
1997-11-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: blended SELEX
|
US5300294A
(en)
|
1990-06-27 |
1994-04-05 |
Smithkline Beecham Corporation |
Method of treating prostatic adenocarcinoma
|
US5385936A
(en)
|
1990-07-12 |
1995-01-31 |
The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services |
Gossypol acetic acid for the treatment of cancer
|
US5023264A
(en)
|
1990-07-16 |
1991-06-11 |
American Home Products Corporation |
Rapamycin oximes
|
NZ239142A
(en)
|
1990-08-01 |
1994-05-26 |
Merrell Dow Pharma |
4-amino-delta-4-steroids; preparatory processes and pharmaceutical compositions
|
US5023263A
(en)
|
1990-08-09 |
1991-06-11 |
American Home Products Corporation |
42-oxorapamycin
|
US5612205A
(en)
|
1990-08-29 |
1997-03-18 |
Genpharm International, Incorporated |
Homologous recombination in mammalian cells
|
PT98990A
(en)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
|
US5221670A
(en)
|
1990-09-19 |
1993-06-22 |
American Home Products Corporation |
Rapamycin esters
|
US5233036A
(en)
|
1990-10-16 |
1993-08-03 |
American Home Products Corporation |
Rapamycin alkoxyesters
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
CA2108575C
(en)
|
1991-04-16 |
2002-10-22 |
Kouichi Nakamichi |
Method of manufacturing solid dispersion
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
US5162333A
(en)
|
1991-09-11 |
1992-11-10 |
American Home Products Corporation |
Aminodiesters of rapamycin
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
US5264427A
(en)
|
1992-01-29 |
1993-11-23 |
Research Corporation Technologies, Inc. |
20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
|
US5177203A
(en)
|
1992-03-05 |
1993-01-05 |
American Home Products Corporation |
Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
|
WO1993020097A1
(en)
|
1992-03-31 |
1993-10-14 |
British Technology Group Ltd. |
17-substituted steroids useful in cancer treatment
|
US5604213A
(en)
|
1992-03-31 |
1997-02-18 |
British Technology Group Limited |
17-substituted steroids useful in cancer treatment
|
AU672978B2
(en)
|
1992-05-20 |
1996-10-24 |
Merck & Co., Inc. |
4-azasteroid 5-alpha-reductase inhibitors
|
US5237064A
(en)
|
1992-05-20 |
1993-08-17 |
Merck & Co., Inc. |
Process for producing 7β-substituted-aza-5αandrostan-3-ones
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
US6042828A
(en)
|
1992-09-07 |
2000-03-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Humanized antibodies to ganglioside GM2
|
DE4232681C2
(en)
|
1992-09-29 |
1994-11-24 |
Sigma Tau Ind Farmaceuti |
17-phenyl and 17-furyl-14beta, 5alpha-androstane and androsten derivatives, processes for their preparation and pharmaceutical composition containing them
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5489680A
(en)
|
1992-10-13 |
1996-02-06 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480988A
(en)
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5480989A
(en)
|
1992-10-13 |
1996-01-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5434260A
(en)
|
1992-10-13 |
1995-07-18 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5411967A
(en)
|
1992-10-13 |
1995-05-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5302584A
(en)
|
1992-10-13 |
1994-04-12 |
American Home Products Corporation |
Carbamates of rapamycin
|
US5262423A
(en)
|
1992-10-29 |
1993-11-16 |
American Home Products Corporation |
Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
US5260300A
(en)
|
1992-11-19 |
1993-11-09 |
American Home Products Corporation |
Rapamycin carbonate esters as immuno-suppressant agents
|
US5504091A
(en)
|
1993-04-23 |
1996-04-02 |
American Home Products Corporation |
Biotin esters of rapamycin
|
CA2161531A1
(en)
|
1993-04-30 |
1994-11-10 |
Donald C. Malins |
Dna profiles as an indicator of cellular redox potential and cancer risk
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
US5837832A
(en)
|
1993-06-25 |
1998-11-17 |
Affymetrix, Inc. |
Arrays of nucleic acid probes on biological chips
|
US5858659A
(en)
|
1995-11-29 |
1999-01-12 |
Affymetrix, Inc. |
Polymorphism detection
|
US5373014A
(en)
|
1993-10-08 |
1994-12-13 |
American Home Products Corporation |
Rapamycin oximes
|
US5391730A
(en)
|
1993-10-08 |
1995-02-21 |
American Home Products Corporation |
Phosphorylcarbamates of rapamycin and oxime derivatives thereof
|
US5378836A
(en)
|
1993-10-08 |
1995-01-03 |
American Home Products Corporation |
Rapamycin oximes and hydrazones
|
JP4105761B2
(en)
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
Semi-synthetic analog immunomodulator of rapamycin (macrolide)
|
US5385909A
(en)
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Heterocyclic esters of rapamycin
|
US5385908A
(en)
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Hindered esters of rapamycin
|
US5385910A
(en)
|
1993-11-22 |
1995-01-31 |
American Home Products Corporation |
Gem-distributed esters of rapamycin
|
PL314238A1
(en)
|
1993-12-17 |
1996-09-02 |
Sandoz Ltd |
Rapamycin derivatives
|
US5637310A
(en)
|
1993-12-20 |
1997-06-10 |
Smithkline Beecham Corporation |
Method of treating prostatic adenocarcinoma
|
US5389639A
(en)
|
1993-12-29 |
1995-02-14 |
American Home Products Company |
Amino alkanoic esters of rapamycin
|
US5578832A
(en)
|
1994-09-02 |
1996-11-26 |
Affymetrix, Inc. |
Method and apparatus for imaging a sample on a device
|
US5631734A
(en)
|
1994-02-10 |
1997-05-20 |
Affymetrix, Inc. |
Method and apparatus for detection of fluorescently labeled materials
|
IL112778A0
(en)
|
1994-03-04 |
1995-05-26 |
Merck & Co Inc |
Substituted heterocycles, their preparation and pharmaceutical compositions containing them
|
US5362718A
(en)
|
1994-04-18 |
1994-11-08 |
American Home Products Corporation |
Rapamycin hydroxyesters
|
US5571639A
(en)
|
1994-05-24 |
1996-11-05 |
Affymax Technologies N.V. |
Computer-aided engineering system for design of sequence arrays and lithographic masks
|
US5463048A
(en)
|
1994-06-14 |
1995-10-31 |
American Home Products Corporation |
Rapamycin amidino carbamates
|
US5556752A
(en)
|
1994-10-24 |
1996-09-17 |
Affymetrix, Inc. |
Surface-bound, unimolecular, double-stranded DNA
|
US6974666B1
(en)
|
1994-10-21 |
2005-12-13 |
Appymetric, Inc. |
Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
|
US5491231A
(en)
|
1994-11-28 |
1996-02-13 |
American Home Products Corporation |
Hindered N-oxide esters of rapamycin
|
US5563145A
(en)
|
1994-12-07 |
1996-10-08 |
American Home Products Corporation |
Rapamycin 42-oximes and hydroxylamines
|
US5599695A
(en)
|
1995-02-27 |
1997-02-04 |
Affymetrix, Inc. |
Printing molecular library arrays using deprotection agents solely in the vapor phase
|
US6130364A
(en)
|
1995-03-29 |
2000-10-10 |
Abgenix, Inc. |
Production of antibodies using Cre-mediated site-specific recombination
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
US6113898A
(en)
|
1995-06-07 |
2000-09-05 |
Idec Pharmaceuticals Corporation |
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
|
DE69624921T2
(en)
|
1995-06-09 |
2003-09-11 |
Novartis Ag |
rapamycin derivatives
|
US5856174A
(en)
|
1995-06-29 |
1999-01-05 |
Affymetrix, Inc. |
Integrated nucleic acid diagnostic device
|
AU704933B2
(en)
|
1995-10-19 |
1999-05-06 |
Merck & Co., Inc. |
16-substituted-6-aza-steroid 5-alpha-reductase inhibitors
|
US5780462A
(en)
|
1995-12-27 |
1998-07-14 |
American Home Products Corporation |
Water soluble rapamycin esters
|
JP2002515738A
(en)
|
1996-01-23 |
2002-05-28 |
アフィメトリックス,インコーポレイティド |
Nucleic acid analysis
|
WO1997029212A1
(en)
|
1996-02-08 |
1997-08-14 |
Affymetrix, Inc. |
Chip-based speciation and phenotypic characterization of microorganisms
|
US6458530B1
(en)
|
1996-04-04 |
2002-10-01 |
Affymetrix Inc. |
Selecting tag nucleic acids
|
EP0937082A2
(en)
|
1996-07-12 |
1999-08-25 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
US6368598B1
(en)
|
1996-09-16 |
2002-04-09 |
Jcrt Radiation Oncology Support Services, Inc. |
Drug complex for treatment of metastatic prostate cancer
|
US5994334A
(en)
|
1997-02-05 |
1999-11-30 |
University Of Maryland |
Androgen synthesis inhibitors
|
DE69837903T2
(en)
|
1997-08-11 |
2008-02-14 |
Pfizer Products Inc., Groton |
Solid pharmaceutical dispersions with increased bioavailability
|
US5994335A
(en)
|
1997-10-17 |
1999-11-30 |
The University Of Maryland, Baltimore |
17-azolyl steroids useful as androgen synthesis inhibitors
|
US20030059471A1
(en)
|
1997-12-15 |
2003-03-27 |
Compton Bruce Jon |
Oral delivery formulation
|
ATE479425T1
(en)
|
1998-04-10 |
2010-09-15 |
Mitsubishi Chem Corp |
SOLID DISPERSION CONTAINING SIAL ACID DERIVATIVES
|
US6465445B1
(en)
|
1998-06-11 |
2002-10-15 |
Endorecherche, Inc. |
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
|
DE60039377D1
(en)
|
1999-02-09 |
2008-08-21 |
Pfizer Prod Inc |
Compositions of basic drugs with improved bioavailability
|
AU783158B2
(en)
|
1999-08-24 |
2005-09-29 |
Ariad Pharmaceuticals, Inc. |
28-epirapalogs
|
CA2382545C
(en)
|
1999-08-27 |
2013-08-13 |
Phylos, Inc. |
Methods for encoding and sorting in vitro translated proteins
|
DK1268481T3
(en)
|
1999-09-17 |
2008-05-05 |
Abbott Gmbh & Co Kg |
Inase inhibitors as therapeutic agents
|
CA2669753C
(en)
|
1999-09-30 |
2012-06-26 |
Hollis-Eden Pharmaceuticals, Inc. |
Therapeutic treatment of androgen receptor driven conditions
|
TR200201617T2
(en)
|
1999-12-23 |
2002-10-21 |
Pfizer Products Inc. |
Pharmaceutical compositions that provide enhanced drug concentrations
|
MY138883A
(en)
|
2000-08-29 |
2009-08-28 |
Government Of Malaysia As Represented By The Ministry Of Science Tehnology And Innovation Malaysia |
Use of asiatic acid for treatment of cencer
|
US20020165381A1
(en)
|
2000-11-30 |
2002-11-07 |
Isabelle Ahrens-Fath |
Human androgen receptor variants
|
UA80393C2
(en)
|
2000-12-07 |
2007-09-25 |
Алтана Фарма Аг |
Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
|
AU2002251266A1
(en)
|
2001-04-10 |
2002-10-28 |
Merck Sharp And Dohme Limited |
Inhibitors of akt activity
|
WO2002083139A1
(en)
|
2001-04-10 |
2002-10-24 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
EP1269994A3
(en)
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
US20030054053A1
(en)
|
2001-09-20 |
2003-03-20 |
Charles Young |
Methods and compositions for inhibiting the proliferation of prostate cancer cells
|
ATE360000T1
(en)
|
2001-10-12 |
2007-05-15 |
Univ Johns Hopkins |
OXIME ANALOGUE OF 1-ALPHA,25-DIHYDROXY-VITAMIN-D3 WITH LOW CALCEMIC EFFECT
|
SE0103424D0
(en)
|
2001-10-15 |
2001-10-15 |
Astrazeneca Ab |
Pharmaceutical formulation
|
US20070015713A1
(en)
|
2005-07-14 |
2007-01-18 |
Voyager Pharmaceutical Corporation |
Methods for treating prostate cancer
|
KR100664822B1
(en)
|
2002-02-01 |
2007-01-04 |
화이자 프로덕츠 인코포레이티드 |
Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
|
JP2005523260A
(en)
|
2002-02-01 |
2005-08-04 |
ファイザー・プロダクツ・インク |
Method for producing homogeneous spray-dried solid amorphous drug dispersion using pressure nozzle
|
JP4451136B2
(en)
|
2002-04-08 |
2010-04-14 |
メルク エンド カムパニー インコーポレーテッド |
Akt activity inhibitor
|
US7223738B2
(en)
|
2002-04-08 |
2007-05-29 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
ES2333318T3
(en)
|
2002-08-12 |
2010-02-19 |
Bend Research, Inc. |
PHARMACEUTICAL COMPOSITIONS OF MEDICINES WITH SEMIORDENATED STRUCTURE AND OF POLYMER.
|
US7378403B2
(en)
|
2002-09-03 |
2008-05-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Akt inhibitors, pharmaceutical compositions, and uses thereof
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
JP2006507299A
(en)
|
2002-10-30 |
2006-03-02 |
メルク エンド カムパニー インコーポレーテッド |
Inhibitor of Akt activity
|
TW200500360A
(en)
|
2003-03-01 |
2005-01-01 |
Astrazeneca Ab |
Hydroxymethyl compounds
|
ATE461179T1
(en)
|
2003-04-24 |
2010-04-15 |
Merck Sharp & Dohme |
ACT ACTIVITY INHIBITOR
|
JP2006524254A
(en)
|
2003-04-24 |
2006-10-26 |
メルク エンド カムパニー インコーポレーテッド |
Inhibitor of AKT activity
|
CA2522431A1
(en)
|
2003-04-24 |
2004-11-11 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
EP1631548B1
(en)
|
2003-04-24 |
2009-10-28 |
Merck & Co., Inc. |
Inhibitors of akt activity
|
US7439268B2
(en)
|
2003-07-18 |
2008-10-21 |
Idexx Laboratories |
Compositions containing prodrugs of florfenicol and methods of use
|
MXPA06000017A
(en)
|
2003-07-29 |
2006-03-21 |
Dompe Spa |
Pharmaceutical combination of g-csf and plgf useful for blood stem cell.
|
WO2005018562A2
(en)
|
2003-08-22 |
2005-03-03 |
University Of Virginia Patent Foundation |
Blockade of mtor to prevent a hormonal adaptive response
|
US7605120B2
(en)
|
2003-10-22 |
2009-10-20 |
Amgen Inc. |
Antagonists of the brandykinin B1 receptor
|
CA2546192C
(en)
|
2003-11-17 |
2010-04-06 |
Pfizer Products Inc. |
Pyrrolopyrimidine compounds useful in treatment of cancer
|
JP4585201B2
(en)
|
2004-01-23 |
2010-11-24 |
丸善製薬株式会社 |
Androgen receptor binding inhibitor, hair nourishing agent, sebum secretion inhibitor and prostate hypertrophy inhibitor
|
JP2007526324A
(en)
|
2004-03-02 |
2007-09-13 |
スミスクライン・ビーチャム・コーポレイション |
Inhibitors with AKT activity
|
EP1740556A1
(en)
|
2004-03-26 |
2007-01-10 |
Rigel Pharmaceuticals, Inc. |
Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
|
WO2005098446A2
(en)
|
2004-03-31 |
2005-10-20 |
The Johns Hopkins University |
Biomarkers for ovarian cancer
|
CN1953747A
(en)
|
2004-04-08 |
2007-04-25 |
顶标公司 |
Diphenyl-indol-2-on compounds and their use in the treatment of cancer
|
JP2007532558A
(en)
|
2004-04-09 |
2007-11-15 |
メルク エンド カムパニー インコーポレーテッド |
Inhibitor of Akt activity
|
EP1737861A4
(en)
|
2004-04-09 |
2010-04-28 |
Merck Sharp & Dohme |
Inhibitors of akt activity
|
US7604947B2
(en)
|
2004-06-09 |
2009-10-20 |
Cornell Research Foundation, Inc. |
Detection and modulation of cancer stem cells
|
US20060013873A1
(en)
|
2004-07-16 |
2006-01-19 |
Chih-Chiang Yang |
Bioadhesive dosage form of steroids
|
US7544677B2
(en)
|
2004-08-23 |
2009-06-09 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
WO2006039215A2
(en)
*
|
2004-09-30 |
2006-04-13 |
Janssen Pharmaceutica N.V. |
Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms)
|
CN101115479A
(en)
|
2005-02-14 |
2008-01-30 |
默克公司 |
Inhibitors of akt activity
|
US20100047338A1
(en)
|
2008-03-14 |
2010-02-25 |
Angela Brodie |
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
|
ATE482969T1
(en)
|
2005-03-02 |
2010-10-15 |
Univ Maryland |
3-BETA-HYDROXY-17-(1H-BENZIMIDAZOLE-1-YL)ANDROST - 5,16-DIENE FOR USE IN THE TREATMENT OF PROSTATE DISEASES
|
US20060204588A1
(en)
|
2005-03-10 |
2006-09-14 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
|
DE102005011786A1
(en)
|
2005-03-11 |
2006-09-14 |
Pharmasol Gmbh |
Process for preparing ultrafine submicron suspensions
|
EP1871376A4
(en)
|
2005-04-12 |
2010-04-28 |
Merck Sharp & Dohme |
Inhibitors of akt activity
|
MX2007015578A
(en)
|
2005-06-10 |
2008-03-06 |
Merck & Co Inc |
Inhibitors of akt activity.
|
CN101310185A
(en)
|
2005-09-19 |
2008-11-19 |
约翰·霍普金斯大学 |
Biomarker for prostate cancer
|
EP1951724B1
(en)
|
2005-11-17 |
2011-04-27 |
OSI Pharmaceuticals, Inc. |
FUSED BICYCLIC mTOR INHIBITORS
|
AR057960A1
(en)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
BICYCLE PROTEIN QUINASE INHIBITORS
|
EP1981890A2
(en)
|
2006-01-25 |
2008-10-22 |
OSI Pharmaceuticals, Inc. |
UNSATURATED mTOR INHIBITORS
|
US7943732B2
(en)
|
2006-06-05 |
2011-05-17 |
Intrexon Corporation |
AKT ligands and polynucleotides encoding AKT ligands
|
KR20150041164A
(en)
|
2006-07-06 |
2015-04-15 |
어레이 바이오파마 인크. |
Cyclopenta〔d〕pyrimidines as akt protein kinase inhibitors
|
US20080051380A1
(en)
|
2006-08-25 |
2008-02-28 |
Auerbach Alan H |
Methods and compositions for treating cancer
|
WO2008027855A2
(en)
|
2006-08-30 |
2008-03-06 |
Novartis Ag |
Compositions and methods for modulating mtor signaling
|
CA2700573C
(en)
|
2006-09-26 |
2016-11-22 |
Cedars-Sinai Medical Center |
Cancer stem cell antigen vaccines and methods
|
ATE476966T1
(en)
|
2006-10-17 |
2010-08-15 |
Bend Res Inc |
SOLID DISPERSION WITH POORLY WATER SOLUBLE ACTIVE INGREDIENTS
|
AR064010A1
(en)
|
2006-12-06 |
2009-03-04 |
Merck & Co Inc |
AKT ACTIVITY INHIBITORS
|
WO2008070823A2
(en)
|
2006-12-07 |
2008-06-12 |
University Of South Florida |
Substrate-mimetic akt inhibitor
|
US7960435B2
(en)
|
2006-12-15 |
2011-06-14 |
University Of Maryland, Baltimore |
Anti-cancer agents and androgen inhibition activity compound
|
US7807393B2
(en)
|
2007-01-29 |
2010-10-05 |
Northwestern University |
Biomarkers for prostate cancer
|
UY30892A1
(en)
|
2007-02-07 |
2008-09-02 |
Smithkline Beckman Corp |
AKT ACTIVITY INHIBITORS
|
KR20150002886A
(en)
|
2007-03-07 |
2015-01-07 |
아브락시스 바이오사이언스, 엘엘씨 |
Nanoparticle comprising rapamycin and albumin as anticancer agent
|
WO2008154402A2
(en)
|
2007-06-06 |
2008-12-18 |
University Of Maryland, Baltimore |
Hdac inhibitors and hormone targeted drugs for the treatment of cancer
|
WO2008154382A1
(en)
|
2007-06-06 |
2008-12-18 |
University Of Maryland, Baltimore |
Hdac inhibitors and hormone targeted drugs for the treatment of cancer
|
US20090012045A1
(en)
|
2007-06-26 |
2009-01-08 |
Rigel Pharmaceuticals, Inc. |
Methods of Treating Cell Proliferative Disorders
|
AR067180A1
(en)
|
2007-06-29 |
2009-09-30 |
Gilead Sciences Inc |
ANTIVIRAL COMPOUNDS
|
US8324221B2
(en)
|
2008-01-09 |
2012-12-04 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
US20110105445A1
(en)
*
|
2008-03-12 |
2011-05-05 |
University Of Maryland, Baltimore |
Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
|
US20110118219A1
(en)
*
|
2008-03-25 |
2011-05-19 |
University Of Maryland, Baltimore |
Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
|
US8785423B2
(en)
|
2008-04-14 |
2014-07-22 |
University Of Maryland, Baltimore |
Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
|
ES2836128T3
(en)
|
2008-04-16 |
2021-06-24 |
Univ Johns Hopkins |
Method to determine androgen receptor variants in prostate cancer
|
WO2010008847A2
(en)
|
2008-06-24 |
2010-01-21 |
Takeda Pharmaceutical Company Limited |
Pi3k/m tor inhibitors
|
WO2010089763A2
(en)
|
2008-06-30 |
2010-08-12 |
Reliance Life Sciences Pvt. Ltd. |
Poly(n-vinyl caprolactam-co-acrylamide) microparticles for controlled release applications
|
WO2010006072A2
(en)
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Mtor modulators and uses thereof
|
EP2318040A4
(en)
|
2008-07-24 |
2013-05-01 |
Univ Central Florida Res Found |
Therapy targeting cancer stem cells
|
US9075065B2
(en)
|
2008-09-12 |
2015-07-07 |
Dako Denmark A/S |
Prostate cancer biomarker
|
US8133724B2
(en)
|
2008-09-17 |
2012-03-13 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
|
US8841422B2
(en)
|
2008-09-17 |
2014-09-23 |
University Of Maryland, Baltimore |
Human androgen receptor alternative splice variants
|
CN102202668A
(en)
|
2008-10-31 |
2011-09-28 |
诺瓦提斯公司 |
Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
|
CN101607985B
(en)
|
2008-12-24 |
2013-03-27 |
中国科学院生物物理研究所 |
Monoclonal antibody for anti-human CEA, a composition containing same and application thereof
|
CA2761389A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals, Inc. |
Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
|
WO2010091303A1
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals |
Novel steroidal cyp17 inhibitors/antiandrogens
|
WO2010091299A2
(en)
|
2009-02-05 |
2010-08-12 |
Tokai Pharmaceuticals |
Novel combination cancer therapies
|
US8168652B2
(en)
|
2009-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
PT3130396T
(en)
|
2009-03-27 |
2021-05-12 |
Bend Res Inc |
Spray-drying process
|
BR112012002797A2
(en)
*
|
2009-08-07 |
2019-09-24 |
Tokai Pharmaceuticals Inc |
prostate cancer treatment
|
WO2011059969A2
(en)
*
|
2009-11-13 |
2011-05-19 |
Tokai Pharmaceuticals, Inc. |
Mammalian metabolites of steroids
|
CA2791244A1
(en)
|
2010-03-08 |
2011-09-15 |
Regents Of The University Of Minnesota |
Androgen receptor isoforms and methods
|
US8703712B2
(en)
|
2010-03-18 |
2014-04-22 |
The Uab Research Foundation |
Targeting cancer stem cells with DR5 agonists
|
JP2013534424A
(en)
|
2010-07-06 |
2013-09-05 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッド |
Methods and compounds for the specific inhibition of androgen receptor by double-stranded RNA
|
US20120028972A1
(en)
|
2010-07-30 |
2012-02-02 |
Lilly Wong |
Biomarker assays for detecting or measuring inhibition of tor kinase activity
|
BR112013017635A2
(en)
|
2010-12-16 |
2016-10-11 |
Biomarin Pharm Inc |
cyp11b, cyp17 and / or cyp21 inhibitors
|
US8946409B2
(en)
|
2011-01-27 |
2015-02-03 |
Board Of Regents, The University Of Texas System |
Polycyclic β lactam derivatives for the treatment of cancer
|
US9594086B2
(en)
|
2011-03-22 |
2017-03-14 |
The Johns Hopkins University |
Biomarkers for aggressive prostate cancer
|
CA2841960A1
(en)
|
2011-07-18 |
2013-01-24 |
Tokai Pharmaceuticals, Inc. |
Novel compositions and methods for treating prostate cancer
|
SG11201401471PA
(en)
|
2011-11-30 |
2014-08-28 |
Astrazeneca Ab |
Combination treatment of cancer
|
US20150005265A1
(en)
|
2011-12-22 |
2015-01-01 |
Susan Stewart |
Methods and compositions for combination therapy using p13k/mtor inhibitores
|
EA029563B1
(en)
|
2012-07-27 |
2018-04-30 |
Арагон Фармасьютикалз, Инк. |
Methods and compositions for determining resistance to androgen receptor therapy
|
WO2014047285A1
(en)
|
2012-09-19 |
2014-03-27 |
Paraskevi Giannakakou |
Identifying taxane sensitivity in prostate cancer patients
|
AU2014236135A1
(en)
|
2013-03-14 |
2015-09-10 |
Thomas Jefferson University |
Androgen receptor down-regulating agents and uses thereof
|
US9808472B2
(en)
|
2013-08-12 |
2017-11-07 |
Tokai Pharmaceuticals, Inc. |
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
JP6860476B2
(en)
|
2014-08-25 |
2021-04-14 |
ザ ジョンズ ホプキンズ ユニヴァーシティー |
Methods and Compositions for Prostate Cancer Treatment
|
WO2016172517A1
(en)
|
2015-04-24 |
2016-10-27 |
Tokai Pharmaceuticals, Inc. |
Methods of treating prostate cancer
|